Sorrento Therapeutics (NASDAQ:SRNE) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Down 20.0 %

SRNE stock opened at $0.00 on Monday. Sorrento Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.10.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.